Senseonics touts patient access program for Eversense CGM

SenseonicsSenseonics (NYSE:SENS) said today that it launched the Eversense Bridge Program, which is designed to improve patient access to Senseonics’ Eversense continuous glucose monitoring system.

The company said that the program can help users confirm their insurance benefits and obtain pre-authorization before sensor placement. The Eversense Bridge Program is also meant to help healthcare providers and patients appeal to insurers regarding denied claims.

Get the full story at our sister site, Drug Delivery Business News.

The post Senseonics touts patient access program for Eversense CGM appeared first on MassDevice.

Novo Nordisk seeks FDA nod for oral diabetes pill

Novo Nordisk - updated logoNovo Nordisk (NYSE:NVO) said this week that it submitted applications to the FDA for its oral formulation of semaglutide, a once-daily glucagon-like peptide-1 receptor agonist therapy.

The company is hoping its pill will be approved as an adjunct to diet and exercise to improve blood sugar control in adults with Type 2 diabetes. Novo Nordisk also submitted for approval of an indication related to risk reduction of major adverse cardiovascular events.

Get the full story at our sister site, Drug Delivery Business News.

The post Novo Nordisk seeks FDA nod for oral diabetes pill appeared first on MassDevice.

OptiScan raises $20m for bedside glucose monitoring system

OptiScan Biomedical said today that it closed a $20 million Series E round to support the commercialization of its continuous monitoring system, the OptiScanner 5000, in the U.S.

The company’s device is an automated bedside blood glucose monitor designed for use in the intensive care unit. The system can measure glucose values from a micro-sample of blood without the need for calibration, according to OptiScan.

Get the full story at our sister site, Drug Delivery Business News.

The post OptiScan raises $20m for bedside glucose monitoring system appeared first on MassDevice.

EOFlow wins breakthrough status for wearable closed-loop insulin delivery tech

EOFlowKorean medtech company EOFlow said last week that it won breakthrough status from the FDA for its closed-loop automated insulin delivery system for people with Type 1 diabetes.

The EOPancreas system features a wearable patch, continuous glucose monitoring systems and a closed-loop blood glucose control algorithm.

Get the full story at our sister site, Drug Delivery Business News.

The post EOFlow wins breakthrough status for wearable closed-loop insulin delivery tech appeared first on MassDevice.

GI Dynamics touts results of U.K. study

GI DynamicsGI Dynamics (ASX:GID) said a retrospective study of its EndoBarrier device for patients with type 2 diabetes and obesity shows a significant reduction in HbA1c, weight, liver fat and cardiovascular disease (CVD) risks as well as a reduction in the need for insulin in some patients.

The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract, according to the Lexington, Mass.-based company.

Get the full story on our sister site, Medical Design & Outsourcing.

The post GI Dynamics touts results of U.K. study appeared first on MassDevice.

Xeris launches Ph2 trial of ready-to-use liquid glucagon

Xeris Pharmaceuticals - updatedXeris Pharmaceuticals (NSDQ:XERS) said today that it dosed the first patients in a Phase II trial of its ready-to-use liquid glucagon in people with Type 1 diabetes.

The Chicago-based company expects to report top-line data from the study in the second half of 2019.

Get the full story at our sister site, Drug Delivery Business News.

The post Xeris launches Ph2 trial of ready-to-use liquid glucagon appeared first on MassDevice.

Pops! Diabetes Care launches blood glucose monitoring system

Pops Diabetes Care updated logoPops! Diabetes Care announced today the commercial launch of its blood glucose monitoring system.

The Minneapolis-based company’s device won FDA clearance in December last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Pops! Diabetes Care launches blood glucose monitoring system appeared first on MassDevice.

Tandem addresses anomaly in pivotal trial for closed-loop tech

Tandem Diabetes Care - updatedTandem Diabetes Care (NSDQ:TNDM) said today that it plans to use its remote software update tool to address an anomaly found in an ongoing pivotal trial of its Control-IQ technology.

The anomaly, according to Tandem, relates to how the company’s t:slim X2 insulin pump with Control-IQ technology handles continuous glucose monitoring data under undisclosed conditions. The company reported that the anomaly could impact the system’s prediction of future blood glucose values and automated insulin delivery.

Get the full story at our sister site, Drug Delivery Business News.

The post Tandem addresses anomaly in pivotal trial for closed-loop tech appeared first on MassDevice.

Senseonics inks CGM data deal with Glooko

SenseonicsSenseonics (NYSE:SENS) said today that data from its Eversense continuous glucose monitoring system can be integrated into Glooko‘s diabetes data management tech.

Thanks to the new partnership, Eversense users will be able to view historical glucose trends in Glooko’s mobile and web apps as well as real-time data from the Eversense mobile app, according to Senseonics.

Get the full story at our sister site, Drug Delivery Business News.

The post Senseonics inks CGM data deal with Glooko appeared first on MassDevice.

Tandem shuffles C-suite, beats The Street with Q4 results

Tandem Diabetes Care - updatedTandem Diabetes Care (NSDQ:TNDM) beat estimates on Wall Street today with its fourth-quarter and full-year financial results.

The company also announced today that its CEO, Kim Blickenstaff, plans to assume the role of executive chairman and that COO John Sheridan will become president and CEO on March 1.

Get the full story at our sister site, Drug Delivery Business News.

The post Tandem shuffles C-suite, beats The Street with Q4 results appeared first on MassDevice.